Takeda Pharmaceutical Company announced on Friday that it intended to fund the cash consideration due on completion of the proposed acquisition of Shire from its cash resources and other financing sources.
The Japanese pharmaceuticals giant said that as a result, it had cancelled in full the remaining commitments under the 364-day bridge credit agreement, which it entered into in connection with the acquisition on 8 May.
In addition, certain technical amendments are being made to the term loan credit agreement dated 8 June, the senior short-term loan facility agreement dated 26 October, and the loan agreement with the Japan Bank for International Cooperationdated 3 December entered into by Takeda, the firms board said in its statement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.